Filter By Category
Archives
Share on -
AMBRUTICIN
Generic Name: AMBRUTICIN
ABSTRACT -
Ambruticin is a natural polyketide antifungal agent isolated from myxobacteria such as Sorangium cellulosum. It belongs to the ambruticin family, which is characterized by unusual oxygen heterocycles and a substituted cyclopropyl unit.
Ambruticin has demonstrated antifungal activity in experimental models and is reported to act through disruption of fungal osmoregulation, including activation of the high-osmolarity glycerol pathway. It is not an approved therapeutic drug.
DOSAGE -
Dosage should be determined only by a qualified healthcare professional.
No approved human dosing regimen is established for Ambruticin.
Available information is primarily from microbiology, natural-product, and experimental antifungal studies.
Use should be restricted to research settings and not used as clinical therapy outside an authorized protocol.
SIDE EFFECTS–
Possible side effects are not well characterized in humans. Potential or theoretical effects include:
- Gastrointestinal upset
- Nausea or vomiting
- Headache
- Skin rash
- Liver or kidney laboratory abnormalities
- Infusion or formulation-related reactions if administered experimentally
- Unknown serious toxicities due to limited clinical data
ALLRGIC REACTIONS–
Hypersensitivity to Ambruticin has not been well characterized, but allergic reactions to natural-product antibiotics or formulation excipients are possible.
Symptoms may include:
- Skin rash or hives
- Itching or swelling of the face, lips, tongue, or throat
- Difficulty breathing or chest tightness
- Severe dizziness or fainting
- Unexpected widespread redness, blistering, or peeling skin
Important: Patients who develop an allergic reaction to Ambruticin should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Human drug-interaction data are limited. Caution is needed with:
- Other antifungal agents when used in investigational combinations
- Medicines with hepatotoxic or nephrotoxic potential
- Immunosuppressive agents in patients with systemic fungal disease
- Drugs that alter hepatic metabolism, if experimental systemic exposure is expected
- Any concomitant clinical trial drug unless permitted by the study protocol
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Not approved for routine medical use.
- Confirm species, susceptibility data, and study protocol before experimental use.
- Monitor liver, kidney, and hematologic parameters in any research exposure.
- Safety in pregnancy, lactation, children, and immunocompromised patients is not established.
- Use appropriate laboratory safety procedures when handling.
WARNINGS –
- Do not use as a substitute for approved antifungal therapy.
- Clinical efficacy and safety in humans have not been established.
- Severe or systemic fungal infections require urgent specialist treatment.
- Use only within qualified research or authorized clinical-trial settings.
- Keep out of reach of children.
Share on -
. Developed by